Sitimagene ceradenovec: A gene-based drug for the treatment of operable high-grade glioma

Future Oncology

Volumn 6, Issue 11, 2010, Pages 1691-1710

  Van Putten, Erik Hp ^a   Dirven, Clemens Mf ^a   Van Den Bent, Martin J ^a   Lamfers, Martine Lm ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

adenovirus; Cerepro ; gene therapy; glioma; herpes simplex virus thymidine kinase; sitimagene ceradenovec

Indexed keywords

BETA GALACTOSIDASE; BETA INTERFERON; CASPASE 8; CD135 ANTIGEN; CD86 ANTIGEN; CONNEXIN 43; CYTOCHROME P450 2B1; CYTOSINE DEAMINASE; ENDOSTATIN; FAS LIGAND; FLT3 LIGAND; FLUCYTOSINE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANYLATE KINASE; INTERLEUKIN 2; INTERLEUKIN 4; ONCOLYTIC VIRUS; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; SITIMAGENE CERADENOVEC; TEMOZOLOMIDE; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; APHASIA; APOPTOSIS; ARTICLE; BRAIN ABSCESS; BRAIN EDEMA; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DNA SYNTHESIS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ENZYME PRODRUG THERAPY; FEASIBILITY STUDY; FEVER; GENE CONSTRUCT; GENE INSERTION; GENE OVEREXPRESSION; GENE TRANSFER; GLIOBLASTOMA; HEMIPARESIS; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOSTIMULATION; KIDNEY CARCINOMA; MULTIMODALITY CANCER THERAPY; NEUROTROPISM; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA INTERFERENCE; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDE GENE THERAPY; SURVIVAL TIME; TARGETED GENE REPAIR; TRANSGENE; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; THYMIDINE KINASE;

EID: 78650219018     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.134     Document Type: Article

References (216)

1. Stupp R, Hegi ME, Mason WP et al.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year ana lysis of the EORTC- NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
2. Brem SS, Bierman PJ, Black P et al.: Central nervous system cancers. J. Natl Compr. Canc. Netw. 6(5), 456-504 (2008).
3. Cheng L, Bao S, Rich JN: Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem. Pharmacol. 80(5), 654-665 (2010).
4. Hadjipanayis CG, Van Meir EG: Tumor initiating cells in malignant gliomas: biology and implications for therapy. J. Mol. Med. 87(4), 363-374 (2009).
5. Pearson S, Jia H, Kandachi K: China approves frst gene therapy. Nat. Biotechnol. 22(1), 3-4 (2004).
6. Garber K: China approves world's frst oncolytic virus therapy for cancer treatment. J. Natl Cancer Inst. 98(5), 298-300 (2006).
7. Spaete RR, Frenkel N: The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 30(1), 295-304 (1982).
8. Freese A, Geller A: Infection of cultured striatal neurons with a defective HSV-1 vector: implications for gene therapy. Nucleic Acids Res. 19(25), 7219-7223 (1991).
9. Fraefel C, Song S, Lim F et al.: Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. 70(10), 7190-7197 (1996).
10. Enger PO, Thorsen F, Lonning PE, Bjerkvig R, Hoover F: Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Hum. Gene Ther. 13(9), 1115-1125 (2002).
11. Cunningham J, Oiwa Y, Nagy D, Podsakoff G, Colosi P, Bankiewicz KS: Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant. 9(5), 585-594 (2000).
12. Kofer P, Wiesenhofer B, Rehrl C, Baier G, Stockhammer G, Humpel C: Liposome-mediated gene transfer into established CNS cell lines, primary glial cells, and in vivo. Cell Transplant. 7(2), 175-185 (1998).
13. Boviatsis EJ, Chase M, Wei MX et al.: Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum. Gene Ther. 5(2), 183-191 (1994).
14. Badie B, Hunt K, Economou JS, Black KL: Stereotactic delivery of a recombinant adenovirus into a c6 glioma cell line in a rat brain tumor model. Neurosurgery 35(5), 910-915 (1994).
15. Short MP, Choi BC, Lee JK, Malick A, Breakefeld XO, Martuza RL: Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res. 27(3), 427-439 (1990).
16. Ezzeddine ZD, Martuza RL, Platika D et al.: Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 3(6), 608-614 (1991).
17. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfeld EH, Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256(5063), 1550-1552 (1992).
18. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfeld EH: In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53(1), 83-88 (1993). (Pubitemid 23019380)
19. Vincent AJ, Vogels R, Someren GV et al.: Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors. Hum. Gene Ther. 7(2), 197-205 (1996).
20. Izquierdo M, Cortes M, De Felipe P et al.: Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther. 2(1), 66-69 (1995).
21. Freeman SM, Abboud CN, Whartenby KA et al.: The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modifed. Cancer Res. 53(21), 5274-5283 (1993).
22. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SL: Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl Acad. Sci. USA 91(8), 3054-3057 (1994).
23. Perez-Cruet MJ, Trask T W, Chen SH et al.: Adenovirus-mediated gene therapy of experimental gliomas. J. Neurosci. Res. 39(4), 506-511 (1994).
24. Maron A, Gustin T, Le Roux A et al.: Gene therapy of rat C6 glioma using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene: long-term follow-up by magnetic resonance imaging. Gene Ther. 3(4), 315-322 (1996).
25. Zerrouqi A, Rixe O, Ghoumari AM et al.: Liposomal delivery of the herpes simplex virus thymidine kinase gene in glioma: improvement of cell sensitization to ganciclovir. Cancer Gene Ther. 3(6), 385-392 (1996). (Pubitemid 126732460)
26. Von Eckardstein KL, Patt S, Zhu J, Zhang L, Cervos-Navarro J, Reszka R: Short-term neuropathological aspects of in vivo suicide gene transfer to the F98 rat glioblastoma using liposomal and viral vectors. Histol. Histopathol. 16(3), 735-744 (2001).
27. Hsiao M, Tse V, Carmel J et al.: Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival. Biochem. Biophys. Res. Commun. 233(2), 359-364 (1997).
28. Mizuno M, Yoshida J, Colosi P, Kurtzman G: Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn J. Cancer Res. 89(1), 76-80 (1998).
29. Yoshida J, Mizuno M, Fujii M et al.: Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon b gene using cationic liposomes. Hum. Gene Ther. 15(1), 77-86 (2004).
30. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C: Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol. Ther. 7(6), 851-858 (2003).
31. Germano IM, Fable J, Gultekin SH, Silvers A: Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a Phase I trial in patients with recurrent malignant gliomas. J. Neurooncol. 65(3), 279-289 (2003).
32. Sandmair AM, Loimas S, Puranen P et al.: Thymidine kinase gene therapy for human malignant glioma, using replication-defcient retroviruses or adenoviruses. Hum. Gene Ther. 11(16), 2197-2205 (2000).
33. Klatzmann D, Valery CA, Bensimon G et al.: A Phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study group on gene therapy for glioblastoma. Hum. Gene Ther. 9(17), 2595-2604 (1998).
34. Izquierdo M, Martin V, De Felipe P et al.: Human malignant brain tumor response to herpes simplex thymidine kinase (HSVTK)/ ganciclovir gene therapy. Gene Ther. 3(6), 491-495 (1996).
35. Ram Z, Culver KW, Oshiro EM et al.: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3(12), 1354-1361 (1997).
36. Shand N, Weber F, Mariani L et al.: A Phase I-II clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. Gli328 European-Canadian study group. Hum. Gene Ther. 10(14), 2325-2335 (1999).
37. Adachi N, Konu Dl, Frei K, Yonekawa Y: The HSV-TK/GCV gene therapy in fve cases of recurrent glioblastoma multiforme. No Shinkei Geka 28(10), 865-871 (2000).
38. Harsh GR, Deisboeck TS, Louis DN et al.: Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J. Neurosurg. 92(5), 804-811 (2000).
39. Packer RJ, Raffel C, Villablanca JG et al.: Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg. 92(2), 249-254 (2000).
40. Rainov NG: A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11(17), 2389-2401 (2000).
41. Palu G, Cavaggioni A, Calvi P et al.: Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther. 6(3), 330-337 (1999).
42. Colombo F, Barzon L, Franchin E et al.: Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther. 12(10), 835-848 (2005).
43. Trask TW, Trask RP, Aguilar-Cordova E et al.: Phase I study of adenoviral delivery of the HSV-TK gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 1(2), 195-203 (2000).
44. Lang FF, Bruner JM, Fuller GN et al.: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. 21(13), 2508-2518 (2003).
45. Immonen A, Vapalahti M, Tyynela K et al.: AdvHSV-TK gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. 10(5), 967-972 (2004).
46. Prados MD, Mcdermott M, Chang SM et al.: Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a Phase I/II multi-institutional trial. J. Neurooncol. 65(3), 269-278 (2003).
47. Chiocca EA, Smith KM, Mckinney B et al.: A Phase I, dose-escalation, multi-institutional trial of Ad. hIFN-fi gene therapy for recurrent malignant glioma: safety and correlative molecular results. Mol. Ther. 16(3), 618-626 (2008).
48. Voges J, Reszka R, Gossmann A et al.: Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. 54(4), 479-487 (2003).
49. Barzon L, Pacenti M, Franchin E, Colombo F, Palu G: HSV-TK/IL-2 gene therapy for glioblastoma multiforme. Methods Mol. Biol. 542, 529-549 (2009).
50. Niranjan A, Moriuchi S, Lunsford LD et al.: Effective treatment of experimental glioblastoma by HSV vector-mediated TNF a and HSV-TK gene transfer in combination with radiosurgery and ganciclovir administration. Mol. Ther. 2(2), 114-120 (2000).
51. Niranjan A, Wolfe D, Tamura M et al.: Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery Mol. Ther. 8(4), 530-542 (2003).
52. Moriuchi S, Glorioso JC, Maruno M et al.: Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IKBa and HSV thymidine kinase. Cancer Gene Ther. 12(5), 487-496 (2005).
53. Aboody KS, Brown A, Rainov NG et al.: Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl Acad. Sci. USA 97(23), 12846-12851 (2000).
54. Nakamizo A, Marini F, Amano T et al.: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65(8), 3307-3318 (2005).
55. Lamfers M, Idema S, Van Milligen F et al.: Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection. Cancer Lett. 274(1), 78-87 (2009).
56. Rath P, Shi H, Maruniak JA, Litofsky NS, Maria BL, Kirk MD: Stem cells as vectors to deliver HSV/Tk gene therapy for malignant gliomas. Curr. Stem Cell Res. Ther. 4(1), 44-49 (2009).
57. Uchibori R, Okada T, Ito T et al.: Retroviral vector-producing mesenchymal stem cells for targeted suicide. Cancer Gene Ther. J. Gene Med. 11(5), 373-381 (2009).
58. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY: Intratumoral 5-fuorouracil produced by cytosine deaminase/5-fuorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 62(3), 773-780 (2002).
59. Ge K, Xu L, Zheng Z, Xu D, Sun L, Liu X: Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fuorocytosine. Int. J. Cancer 71(4), 675-679 (1997).
60. Ichikawa T, Tamiya T, Adachi Y et al.: In vivo effcacy and toxicity of 5-fuorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther. 7(1), 74-82 (2000).
61. Chang DY, Yoo SW, Hong Y et al.: The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int. J. Cancer 127(8), 1975-1983 (2010).
62. Wang ZH, Zagzag D, Zeng B, Kolodny EH: In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-a. J. Neuropathol. Exp. Neurol. 58(8), 847-858 (1999).
63. Aghi M, Kramm CM, Chou TC, Breakefeld XO, Chiocca EA: Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fuorocytosine/cytosine deaminase gene therapies. J. Natl Cancer Inst. 90(5), 370-380 (1998).
64. Rogulski KR, Zhang K, Kolozsvary A, Kim JH, Freytag SO: Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin. Cancer Res. 3(11), 2081-2088 (1997).
65. Chang JW, Lee H, Kim E, Lee Y, Chung SS, Kim JH: Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma. Neurosurgery 47(4), 931-938; discussion 938-939 (2000).
66. Wei MX, Tamiya T, Chase M et al.: Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome p450 2B1 gene. Hum. Gene Ther. 5(8), 969-978 (1994).
67. Wei MX, Tamiya T, Rhee RJ, Breakefeld XO, Chiocca EA: Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/ cytochrome p450 2b1 cancer gene therapy paradigm. Clin. Cancer Res. 1(10), 1171-1177 (1995).
68. Manome Y, Wen PY, Chen L et al.: Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome p450 2B1 gene together with cyclophosphamide. Gene Ther. 3(6), 513-520 (1996).
69. Mercapide J, Rappa G, Anzanello F, King J, Fodstad O, Lorico A: Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. Int. J. Cancer 126(5), 1206-1215 (2010).
70. Ohgaki H, Dessen P, Jourde B et al.: Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64(19), 6892-6899 (2004).
71. Badie B, Drazan KE, Kramar MH, Shaked A, Black KL: Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol. Res. 17(3), 209-216 (1995).
72. Kock H, Harris MP, Anderson SC et al.: Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int. J. Cancer 67(6), 808-815 (1996).
73. Li H, Lochmuller H, Yong V W, Karpati G, Nalbantoglu J: Adenovirus-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. J. Neuropathol. Exp. Neurol. 56(8), 872-878 (1997).
74. Cirielli C, Inyaku K, Capogrossi MC, Yuan X, Williams JA: Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. J. Neurooncol. 43(2), 99-108 (1999).
75. Abe T, Wakimoto H, Bookstein R, Maneval DC, Chiocca EA, Basilion JP: Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Ther. 9(3), 228-235 (2002).
76. Gomez-Manzano C, Fueyo J, Kyritsis AP et al.: Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 56(4), 694-699 (1996).
77. Fueyo J, Gomez-Manzano C, Yung WK et al.: Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifes the transformed phenotype of glioma cells. Oncogene 12(1), 103-110 (1996).
78. Chen J, Willingham T, Shuford M et al.: Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene 13(7), 1395-1403 (1996).
79. Fueyo J, Gomez-Manzano C, Yung WK et al.: Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat. Med. 4(6), 685-690 (1998).
80. Park KH, Lee J, Yoo CG et al.: Application of p27 gene therapy for human malignant glioma potentiated by using mutant p27. J. Neurosurg. 101(3), 505-510 (2004).
81. Wang TJ, Huang MS, Hong CY, Tse V, Silverberg GD, Hsiao M: Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ. Biochem. Biophys. Res. Commun. 287(1), 173-180 (2001).
82. You Y, Geng X, Zhao P et al.: Evaluation of combination gene therapy with PTEN and antisense HTERT for malignant glioma in vitro and xenografts. Cell. Mol. Life Sci. 64(5), 621-631 (2007).
83. Ambar BB, Frei K, Malipiero U et al.: Treatment of experimental glioma by administration of adenoviral vectors expressing fas ligand. Hum. Gene Ther. 10(10), 1641-1648 (1999).
84. Lee J, Hampl M, Albert P, Fine HA: Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 4(4), 312-323 (2002).
85. Kim CY, Jeong M, Mushiake H et al.: Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther. 13(4), 330-338 (2006).
86. Naumann U, Waltereit R, Schulz JB, Weller M: Adenoviral (full-length) APO2L/ TRAIL gene transfer is an ineffective treatment strategy for malignant glioma. J. Neurooncol. 61(1), 7-15 (2003).
87. Shinoura N, Koike H, Furitu T et al.: Adenovirus-mediated transfer of caspase-8 augments cell death in gliomas: implication for gene therapy. Hum. Gene Ther. 11(8), 1123-1137 (2000).
88. Kondo S, Ishizaka Y, Okada T et al.: FADD gene therapy for malignant gliomas in vitro and in vivo. Hum. Gene Ther. 9(11), 1599-1608 (1998).
89. Gurzov EN, Izquierdo M: Cyclin E1 knockdown induces apoptosis in cancer cells. Neurol Res. 28(5), 493-499 (2006).
90. Shinoura N, Sakurai S, Asai A, Kirino T, Hamada H: Caspase-9 transduction overrides the resistance mechanism against p53-mediated apoptosis in U-87MG glioma cells. Neurosurgery 49(1), 177-186 (2001).
91. Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C, Norris JS, Dong JY: Enhanced apoptosis of glioma cell lines is achieved by co-delivering FASL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 10(11), 814-822 (2003).
92. Shinoura N, Saito K, Yoshida Y et al.: Adenovirus-mediated transfer of BAX with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas. Cancer Gene Ther. 7(5), 739-748 (2000).
93. Shinoura N, Furitsu T, Asai A, Kirino T, Hamada H: Co-transduction of p27Kip1 strongly augments FAS ligand- and caspase-8-mediated apoptosis in U-373MG glioma cells. Anticancer Res. 21(5), 3261-3268 (2001). (Pubitemid 34224226)
94. Shinoura N, Sakurai S, Shibasaki F, Asai A, Kirino T, Hamada H: Co-transduction of Apaf-1 and caspase-9 highly enhances p53-mediated apoptosis in gliomas. Br. J. Cancer 86(4), 587-595 (2002).
95. Kim SK, Wang KC, Cho BK et al.: Interaction between p53 and p16 expressed by adenoviral vectors in human malignant glioma cell lines. J. Neurosurg. 97(1), 143-150 (2002).
96. Sasportas LS, Kasmieh R, Wakimoto H et al.: Assessment of therapeutic effcacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc. Natl Acad. Sci. USA 106(12), 4822-4827 (2009).
97. Shah K, Bureau E, Kim DE et al.: Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann. Neurol. 57(1), 34-41 (2005).
98. Kim SM, Lim JY, Park SI et al.: Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res. 68(23), 9614-9623 (2008).
99. Tsurushima H, Yuan X, Dillehay LE, Leong KW: Radio-responsive gene therapy for malignant glioma cells without the radiosensitive promoter: caspase-3 gene therapy combined with radiation. Cancer Lett. 246(1-2), 318-323 (2007).
100. Arafat WO, Buchsbaum DJ, Gomez-Navarro J et al.: An adenovirus encoding proapoptotic bax synergistically radiosensitizes malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 55(4), 1037-1050 (2003).
101. Badie B, Goh CS, Klaver J, Herweijer H, Boothman DA: Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Ther. 6(2), 155-162 (1999).
102. Tsurushima H, Yuan X, Dillehay LE, Leong KW: Radiation-inducible caspase-8 gene therapy for malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 71(2), 517-525 (2008).
103. Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K: Targeting multiple pathways in gliomas with stem cell and viral delivered s-TRAIL and temozolomide. Mol. Cancer Ther. 7(11), 3575-3585 (2008).
104. Uzzaman M, Keller G, Germano IM: Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells. J. Neurosurg. 106(4), 646-651 (2007).
105. Tsurushima H, Yuan X, Dillehay LE, Leong KW: Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors. Cancer Gene Ther. 14(8), 706-716 (2007).
106. Ram Z, Walbridge S, Heiss JD, Culver K W, Blaese RM, Oldfeld EH: In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J. Neurosurg. 80(3), 535-540 (1994).
107. Wei MX, Tamiya T, Hurford RK Jr., Boviatsis EJ, Tepper RI, Chiocca EA: Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum. Gene Ther. 6(4), 437-443 (1995).
108. Saleh M, Wiegmans A, Malone Q, Stylli SS, Kaye AH: Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J. Natl Cancer Inst. 91(5), 438-445 (1999).
109. Saleh M, Jonas NK, Wiegmans A, Stylli SS: The treatment of established intracranial tumors by in situ retroviral IFN-g transfer. Gene Ther. 7(20), 1715-1724 (2000).
110. Sampson JH, Ashley DM, Archer GE et al.: Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 41(6), 1365-1372; discussion 1372-1373 (1997).
111. Benedetti S, Dimeco F, Pollo B et al.: Limited effcacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum. Gene Ther. 8(11), 1345-1353 (1997).
112. Wei MX, Li F, Ono Y, Gauldie J, Chiocca EA: Effects on brain tumor cell proliferation by an adenovirus vector that bears the interleukin-4 gene. J. Neurovirol. 4(2), 237-241 (1998).
113. Liu Y, Ehtesham M, Samoto K et al.: In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther. 9(1), 9-15 (2002).
114. Donson AM, Foreman NK: Adenovirus mediated gene therapy in a glioblastoma vaccine model; specifc antitumor immunity and abrogation of immunosuppression. J. Neurooncol. 40(3), 205-214 (1998).
115. Ehtesham M, Samoto K, Kabos P et al.: Treatment of intracranial glioma with in situ interferon-g and tumor necrosis factor-a gene transfer. Cancer Gene Ther. 9(11), 925-934 (2002).
116. Kanno H, Hattori S, Sato H et al.: Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-g. Cancer Gene Ther. 6(2), 147-154 (1999).
117. Herrlinger U, Jacobs A, Quinones A et al.: Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Hum. Gene Ther. 11(10), 1429-1438 (2000).
118. Pluhar GE, Grogan PT, Seiler C et al.: Antitumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 28(19), 3371-3378 (2010).
119. Lefranc F, Cool V, Velu T, Brotchi J, De Witte O: Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective antitumoral immune response against the 9L rat gliosarcoma model. Int. J. Oncol. 20(5), 1077-1085 (2002).
120. Herrlinger U, Kramm CM, Johnston KM et al.: Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther. 4(6), 345-352 (1997).
121. Okada H, Giezeman-Smits KM, Tahara H et al.: Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVTK tumor vaccine. Gene Ther. 6(2), 219-226 (1999).
122. Parney IF, Petruk KC, Zhang C, Farr-Jones M, Sykes DB, Chang LJ: Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum. Gene Ther. 8(9), 1073-1085 (1997).
123. Ali S, Curtin JF, Zirger JM et al.: Infammatory and anti-glioma effects of an adenovirus expressing human soluble FMS-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol. Ther. 10(6), 1071-1084 (2004).
124. Yoshida J, Mizuno M, Nakahara N, Colosi P: Antitumor effect of an adeno-associated virus vector containing the human interferon-b gene on experimental intracranial human glioma. Jpn J. Cancer Res. 93(2), 223-228 (2002).
125. Streck CJ, Dickson PV, Ng CY et al.: Antitumor effcacy of AAV-mediated systemic delivery of interferon-b. Cancer Gene Ther. 13(1), 99-106 (2006).
126. Maguire CA, Meijer DH, Leroy SG et al.: Preventing growth of brain tumors by creating a zone of resistance. Mol. Ther. 16(10), 1695-1702 (2008).
127. Meijer DH, Maguire CA, Leroy SG, Sena-Esteves M: Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-b. Cancer Gene Ther. 16(8), 664-671 (2009).
128. Okada H, Miyamura K, Itoh T et al.: Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Ther. 3(11), 957-964 (1996).
129. Ali S, King GD, Curtin JF et al.: Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 65(16), 7194-7204 (2005).
130. Puntel M, Muhammad AK, Candolf M et al.: A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. J. Virol. 84(12), 6007-6017 (2010).
131. Sasaki M, Wizigmann-Voos S, Risau W, Plate KH: Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas. Int. J. Dev. Neurosci. 17(5-6), 579-591 (1999).
132. Saiki M, Mima T, Takahashi JC et al.: Adenovirus-mediated gene transfer of a truncated form of fbroblast growth factor receptor inhibits growth of glioma cells both in vitro and in vivo. J. Neurooncol. 44(3), 195-203 (1999).
133. Ciafre SA, Niola F, Wannenes F, Farace MG: An anti-VEGF ribozyme embedded within the adenoviral VAI sequence inhibits glioblastoma cell angiogenic potential in vitro. J. Vasc. Res. 41(3), 220-228 (2004).
134. Lakka SS, Gondi CS, Yanamandra N et al.: Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells effciently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res. 63(10), 2454-2461 (2003).
135. Gondi CS, Lakka SS, Yanamandra N et al.: Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 22(38), 5967-5975 (2003).
136. Kang X, Xiao X, Harata M et al.: Antiangiogenic activity of bai1 in vivo: implications for gene therapy of human glioblastomas. Cancer Gene Ther. 13(4), 385-392 (2006).
137. Niola F, Evangelisti C, Campagnolo L et al.: A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol. Ther. 5(2), 174-179 (2006).
138. Tanaka T, Cao Y, Folkman J, Fine HA: Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 58(15), 3362-3369 (1998).
139. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA: Viral vector-mediated transduction of a modifed platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med. 3(4), 437-442 (1997).
140. Yanamandra N, Kondraganti S, Gondi CS et al.: Recombinant adeno-associated virus (RAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int. J. Cancer 115(6), 998-1005 (2005).
141. Ma HI, Lin SZ, Chiang YH et al.: Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther. 9(1), 2-11 (2002).
142. Harding TC, Lalani AS, Roberts BN et al.: A AV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. Mol. Ther. 13(5), 956-966 (2006).
143. Hirko AC, Buethe DD, Meyer EM, Hughes JA: Plasmid delivery in the rat brain. Biosci. Rep. 22(2), 297-308 (2002).
144. Barnett FH, Scharer-Schuksz M, Wood M, Yu X, Wagner TE, Friedlander M: Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure. Gene Ther. 11(16), 1283-1289 (2004).
145. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS: Downregulation of uPA, upar and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol. 1(2), 165-176 (2004).
146. Lakka SS, Gondi CS, Yanamandra N et al.: Inhibition of cathepsin b and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23(27), 4681-4689 (2004).
147. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS: Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and upa retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin. Cancer Res. 13(14), 4051-4060 (2007).
148. Puumalainen AM, Vapalahti M, Agrawal RS et al.: b-galactosidase gene transfer to human malignant glioma in vivo using replication-defcient retroviruses and adenoviruses. Hum. Gene Ther. 9(12), 1769-1774 (1998).
149. Markert JM, Liechty PG, Wang W et al.: Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther. 17(1), 199-207 (2009).
150. Markert JM, Medlock MD, Rabkin SD et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. 7(10), 867-874 (2000).
151. Aghi MK, Chiocca EA: Phase Ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol. Ther. 17(1), 8-9 (2009).
152. Papanastassiou V, Rampling R, Fraser M et al.: The potential for effcacy of the modifed (ICP 34.5-) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 9(6), 398-406 (2002).
153. Rampling R, Cruickshank G, Papanastassiou V et al.: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7(10), 859-866 (2000).
154. Chiocca EA, Abbed KM, Tatter S et al.: A Phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. 10(5), 958-966 (2004).
155. Csatary LK, Bakacs T: Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 281(17), 1588-1589 (1999).
156. Csatary LK, Gosztonyi G, Szeberenyi J et al.: MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neurooncol. 67(1-2), 83-93 (2004).
157. Wagner S, Csatary CM, Gosztonyi G et al.: Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS 114(10), 731-743 (2006).
158. Freeman AI, Zakay-Rones Z, Gomori JM et al.: Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13(1), 221-228 (2006).
159. Forsyth P, Roldan G, George D et al.: A Phase I trial of intratumoral administration of reovirus in patients with histologically confrmed recurrent malignant gliomas. Mol. Ther. 16(3), 627-632 (2008).
160. Parker JN, Bauer DF, Cody JJ, Markert JM: Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6(3), 558-569 (2009).
161. Haseley A, Alvarez-Breckenridge C, Chaudhury AR, Kaur B: Advances in oncolytic virus therapy for glioma. Recent Pat. CNS Drug Discov. 4(1), 1-13 (2009).
162. Robbins JM, Ostertag D, Amundson K et al.: Intratumoral conversion of fucytosine to 5-fuorouracil using a novel MLV-based replication-competent retroviral vector carrying the cytosine deaminase gene (TOCA 511) in an immunocompetent model of glioblastoma. J. Clin. Oncol. 28, E13506 (2010).
163. Barr E, Carroll J, Kalynych AM et al.: Effcient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther. 1(1), 51-58 (1994).
164. Tyynela K, Sandmair AM, Turunen M et al.: Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model. Cancer Gene Ther. 9(11), 917-924 (2002).
165. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46(10), 5276-5281 (1986).
166. Aghi M, Hochberg F, Breakefeld XO: Prodrug activation enzymes in cancer gene therapy J. Gene Med. 2(3), 148-164 (2000).
167. Maatta AM, Samaranayake H, Pikkarainen J, Wirth T, Yla-Herttuala S: Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr. Gene Ther. 9(5), 356-367 (2009).
168. Moolten FL, Wells JM, Heyman RA, Evans RM: Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum. Gene Ther. 1(2), 125-134 (1990).
169. Wu JK, Cano WG, Meylaerts SA, Qi P, Vrionis F, Cherington V: Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 35(6), 1094-1102; discussion 1102-1103 (1994).
170. Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefeld XO, Martuza RL: Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res. 33(3), 493-503 (1992).
171. Dilber MS, Abedi MR, Christensson B et al.: Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 57(8), 1523-1528 (1997).
172. Rubsam LZ, Boucher PD, Murphy PJ, Kukuruga M, Shewach DS: Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. 59(3), 669-675 (1999).
173. Sandmair AM, Turunen M, Tyynela K et al.: Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions. Cancer Gene Ther. 7(3), 413-421 (2000).
174. Namba H, Iwadate Y, Tagawa M et al.: Evaluation of the bystander effect in experimental brain tumors bearing herpes simplex virus-thymidine kinase gene by serial magnetic resonance imaging. Hum. Gene Ther. 7(15), 1847-1852 (1996).
175. Elshami AA, Saavedra A, Zhang H et al.: Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3(1), 85-92 (1996).
176. Touraine RL, Vahanian N, Ramsey WJ, Blaese RM: Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor effcacy in vivo by pharmacologic manipulation of gap junctions. Hum. Gene Ther. 9(16), 2385-2391 (1998).
177. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H: Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl Acad. Sci. USA 93(5), 1831-1835 (1996).
178. Bi WL, Parysek LM, Warnick R, Stambrook PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV TK retroviral gene therapy. Hum. Gene Ther. 4(6), 725-731 (1993). (Pubitemid 24305766)
179. Asklund T, Appelskog IB, Ammerpohl O et al.: Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVTK gene. Exp. Cell Res. 284(2), 185-195 (2003).
180. Langford G, Dayan A, Yla-Herttuala S, Eckland D: A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro) after intracerebral administration. J. Gene Med. 11(6), 468-476 (2009).
181. Rainov NG, Kramm CM, Aboody-Guterman K et al.: Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther. 3(2), 99-106 (1996).
182. Pulkkanen KJ, Parkkinen JJ, Laukkanen JM et al.: HSV-TK gene therapy for human renal cell carcinoma in nude mice. Cancer Gene Ther. 8(7), 529-536 (2001).
183. Laurema A, Riekkinen M, Heikura T et al.: The administration of an adenoviral thymidine kinase suicide gene to the uterine artery of rabbits does not affect fertility: a safety study of pregnant and nonpregnant rabbits and their offspring. J. Gene Med. 10(9), 1005-1011 (2008).
184. Duzgunes N: Sitimagene ceradenovec, a gene therapeutic for the treatment of glioma. Curr. Opin Mol. Ther. 10(2), 187-195 (2008).
185. Lee J, Kotliarova S, Kotliarov Y et al.: Tumor stem cells derived from glioblastomas cultured in BFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9(5), 391-403 (2006).
186. Singh SK, Clarke ID, Terasaki M et al.: Identifcation of a cancer stem cell in human brain tumors. Cancer Res. 63(18), 5821-5828 (2003).
187. Wang J, Miletic H, Sakariassen PO et al.: A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer 9, 465 (2009).
188. Pizzato M, Franchin E, Calvi P et al.: Production and characterization of a bicistronic moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. Gene Ther. 5(7), 1003-1007 (1998).
189. Wang WJ, Tai CK, Kasahara N, Chen TC: Highly effcient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum. Gene Ther. 14(2), 117-127 (2003).
190. Tai CK, Wang WJ, Chen TC, Kasahara N: Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival beneft in experimental glioma. Mol. Ther. 12(5), 842-851 (2005).
191. Greco O, Joiner MC, Doleh A, Powell AD, Hillman GG, Scott SD: Hypoxia- and radiation-activated Cre/LOXP 'molecular switch' vectors for gene therapy of cancer. Gene Ther. 13(3), 206-215 (2006).
192. Wang W, Tai CK, Kershaw AD et al.: Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg. Focus 20(4), E25 (2006).
193. Huszthy PC, Immervoll H, Wang J et al.: Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment. Gene Ther. 17(2), 202-216 (2010).
194. Rogulski KR, Kim JH, Kim SH, Freytag SO: Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. 8(1), 73-85 (1997).
195. Moriuchi S, Wolfe D, Tamura M et al.: Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther. 9(9), 584-591 (2002).
196. Ardiani A, Sanchez-Bonilla M, Black ME: Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo. Cancer Gene Ther. 17(2), 86-96 (2010).
197. Marconi P, Tamura M, Moriuchi S et al.: Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol. Ther. 1(1), 71-81 (2000).
198. Moriuchi S, Oligino T, Krisky D et al.: Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-a and herpes simplex virus thymidine kinase. Cancer Res. 58(24), 5731-5737 (1998).
199. Ito S, Natsume A, Shimato S et al.: Human neural stem cells transduced with IFN-b and cytosine deaminase genes intensify bystander effect in experimental glioma. Cancer Gene Ther. 17(5), 299-306 (2010).
200. Harada H, Nakagawa K, Iwata S et al.: Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res. 59(15), 3783-3789 (1999).
201. Li H, Alonso-Vanegas M, Colicos MA et al.: Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res. 5(3), 637-642 (1999).
202. Lee A, Dejong G, Guo J, Bu X, Jia WW: Bax expressed from a herpes viral vector enhances the effcacy of N,N-bis(2-hydroxyethyl)-N-nitrosourea treatment in a rat glioma model. Cancer Gene Ther. 7(8), 1113-1119 (2000).
203. Komata T, Kondo Y, Kanzawa T et al.: Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 61(15), 5796-5802 (2001).
204. Mitlianga PG, Gomez-Manzano C, Kyritsis AP, Fueyo J: Overexpression of E2F-1 leads to bax-independent cell death in human glioma cells. Int. J. Oncol. 21(5), 1015-1020 (2002).
205. Zhang Y, Wang C, Zhang Y, Sun M: C6 glioma cells retrovirally engineered to express IL-18 and FAS exert FASL-dependent cytotoxicity against glioma formation. Biochem. Biophys. Res. Commun. 325(4), 1240-1245 (2004).
206. Ho IA, Hui KM, Lam PY: Targeting proliferating tumor cells via the transcriptional control of therapeutic genes. Cancer Gene Ther. 13(1), 44-52 (2006).
207. Kock N, Kasmieh R, Weissleder R, Shah K: Tumor therapy mediated by lentiviral expression of shBcl-2 and s-TRAIL. Neoplasia 9(5), 435-442 (2007).
208. Harding TC, Dickinson PJ, Roberts BN et al.: Enhanced gene transfer effciency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors. Hum. Gene Ther. 17(8), 807-820 (2006).
209. Szentirmai O, Baker CH, Bullain SS et al.: Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation. J. Neurosurg. 108(5), 979-988 (2008).
210. Lakka SS, Rajan M, Gondi C et al.: Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 21(52), 8011-8019 (2002).
211. Mizuno M, Yoshida J, Oyama H, Sugita K: Growth inhibition of glioma cells by liposome-mediated cell transfection with tumor necrosis factor-a gene-its enhancement by prior g-interferon treatment. Neurol. Med. Chir. 32(12), 873-876 (1992).
212. Tseng SH, Hwang LH, Lin SM: Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines. J. Immunother. 20(5), 334-342 (1997).
213. Natsume A, Mizuno M, Ryuke Y, Yoshida J: Antitumor effect and cellular immunity activation by murine interferon-b gene transfer against intracerebral glioma in mouse. Gene Ther. 6(9), 1626-1633 (1999).
214. Natsume A, Tsujimura K, Mizuno M, Takahashi T, Yoshida J: IFN-b gene therapy induces systemic antitumor immunity against malignant glioma. J. Neurooncol. 47(2), 117-124 (2000).
215. Yamini B, Yu X, Pytel P et al.: Adenovirally delivered tumor necrosis factor-a improves the antiglioma effcacy of concomitant radiation and temozolomide therapy. Clin. Cancer Res. 13(20), 6217-6223 (2007).
216. Xu G, Jiang XD, Xu Y et al.: Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol. Int. 33(4), 466-474 (2009).